Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: A meta-analysis

Pulmonary Medicine

Volumn , Issue , 2012, Pages

  Tzouvelekis, Argyris ^a   Galanopoulos, Nikolaos ^a   Bouros, Evangelos ^b   Kolios, George ^b   Zacharis, George ^a   Ntolios, Paschalis ^a   Koulelidis, Andreas ^a   Oikonomou, Anastasia ^a   Bouros, Demosthenes ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; LIVER ENZYME; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; VORICONAZOLE;

ABDOMINAL PAIN; ADULT; ARTICLE; ASPERGILLUS TERREUS; COCHRANE LIBRARY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMBASE; FEMALE; FORCED VITAL CAPACITY; HUMAN; INFECTION; INFORMATION RETRIEVAL; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LUNG DIFFUSION CAPACITY; LUNG MYCOSIS; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; TREATMENT DURATION;

EID: 84874711605     PISSN: 20901836     EISSN: 20901844     Source Type: Journal    
DOI: 10.1155/2012/143637     Document Type: Article

References (33)

1. Steen V. D., Conte C., Owens G. R., Medsger T. A., Severe restrictive lung disease in systemic sclerosis Arthritis and Rheumatism 1994 37 9 1283 1289 (Pubitemid 24320744)
2. Steen V. D., The Many Faces of Scleroderma Rheumatic Disease Clinics of North America 2008 34 1 1 15 (Pubitemid 351329460)
3. Walker U. A., Tyndall A., Czirjk L., Denton C., Farge-Bancel D., Kowal-Bielecka O., Mller-Ladner U., Bocelli-Tyndall C., Matucci-Cerinic M., Riemekasten G., Brckner C., Air P., Scarsi M., Scorza R., Beretta L., Cozzi F., Tiso F., Vonk M. C., Van Den Hoogen F. H. J., Wigley F. M., Hummers L., Nevskaya T., Ananieva L., Miniati I., Tartaglia N., Lomater C., Balbir-Gurman A., Braun-Moscovici Y., Bambara L. M., Caramaschi P., Valentini G., Ruocco L., Krieg T., Hunzelmann N., Varj C., Carriera P. E., Joven B., Iannone F., Lapadula G., Kahan A., Allanore Y., Gabrielli A., Imperatore M., Scheja A., Wollheim F., Damjanov N., Ostojic P., Saar P., Tarner I. H., Ktter I., Bombardieri S., Bazzichi L., Del Papa N., Comina D. P., Lo Monaco A., La Corte R., Hachulla E., Launay D., Distler O., Ciurea A., Sierakowski S., Mitchell H., Silver R. M., Krasowska D., Michalska-Jakubus M., Tikly M., Aboo N., Worm M., Klaus P., Rovensk J., Lukov O., Rozman B., Sipek A., Clemente-Coelho P., Shoenfeld Y., Langewitch P., Da Silva José A. P., Salvador M. J., Kuhn A., Erdmann G., Bev R., Friedl E., Graninger W., Riccieri V., Caporali R., Montecucco C., Vlachoyiannopoulos P., Distler M., Reich K., Majdan M., Wielosz E., Rednic S., Van Laar J. M., Heitmann S., Bruckner A., Himsel A., Riemann J., Meyringer R., Mller A., Martinovic D., Radic M., Sticherling M., Szekanecz Z., Szcs G., Giacomelli R., Marrelli A., Stamenkovic B., Stankovic A., Aringer M., Smolen J. S., Kucharz E. J., Kotulska A. T., Jablonska S., Blasczik M., Jun J. B., Mallia C., Coleiro B., Santamaria V. O., Hinrichs R., Nielsen H., Cossutta R., Ionescu R., Opris D., Steinbrink K., Grundt B., Bajocchi G., Ji.., Lefebvre P. G. D. L. P., Zea Mendoza A. C., Ribi C., Chizzolini C., Wisowska M., Novak S., Indiveri F., Jacobsen S., Frandsen P. B., Gorska I. Z., Tore Gran J., Midtvedt., Ramos F. O., Rajcevska L. D., Bozinovski G., Schffel D., Sunderktter C., Bhm M., Morovi-Vergles J., ulo M. I., Cutolo M., Sulli A., Derk C. T., Jimenez S. A., Siakka P., Sndergaard K., Stengaard-Pedersen K., Cabane J., Tiev K. P., Mihai C., Sfrent-Cornateanu R., Jendro M., Tuvik P., Antivalle M., Randisi G., Seidel M., Clarenbach R., Simsek I., Dinc A., Inanc M., Capraru M. S., Capraru D., Baegil I., Richter J., Alhasani S., Fldvari I., Pinto S., Brando F., Mas A. J., Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database Annals of the Rheumatic Diseases 2007 66 6 754 763 (Pubitemid 46846694)
4. Bouros D., Wells A. U., Nicholson A. G., Colby T. V., Polychronopoulos V., Pantelidis P., Haslam P. L., Vassilakis D. A., Black C. M., Du Bois R. M., Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome American Journal of Respiratory and Critical Care Medicine 2002 165 12 1581 1586 (Pubitemid 34693935)
5. Wells A. U., Hirani N., Interstitial lung disease guideline: the British thoracic society in collaboration with the thoracic society of Australia and New Zealand and the Irish thoracic society Thorax 2008 63 supplement 5 v1 v58
6. Clements P. J., Furst D. E., Wong W. K., Mayes M., White B., Wigley F., Weisman M. H., Barr W., Moreland L. W., Medsger T. A., Steen V., Martin R. W., Collier D., Weinstein A., Lally E., Varga J., Weiner S., Andrews B., Abeles M., Seibold J. R., High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial Arthritis and Rheumatism 1999 42 6 1194 1203 (Pubitemid 29268956)
7. Clements P. J., Seibold J. R., Furst D. E., Mayes M., White B., Wigley F., Weisman M. D., Barr W., Moreland L., Medsger T. A., Steen V., Martin R. W., Collier D., Weinstein A., Lally E., Varga J., Weiner S. R., Andrews B., Abeles M., Wong W. K., High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned Seminars in Arthritis and Rheumatism 2004 33 4 249 263 (Pubitemid 38280824)
8. Hoyles R. K., Ellis R. W., Wellsbury J., Lees B., Newlands P., Goh N. S. L., Roberts C., Desai S., Herrick A. L., McHugh N. J., Foley N. M., Pearson S. B., Emery P., Veale D. J., Denton C. P., Wells A. U., Black C. M., Du Bois R. M., A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma Arthritis and Rheumatism 2006 54 12 3962 3970 (Pubitemid 44955900)
9. Matucci-Cerinic M., Steen V. D., Furst D. E., Seibold J. R., Clinical trials in systemic sclerosis: lessons learned and outcomes Arthritis Research and Therapy 2007 9 2 S7
10. Mouthon L., Berezne A., Guillevin L., Valeyre D., Therapeutic options for systemic sclerosis related interstitial lung diseases Respiratory Medicine 2010 104 supplement 1 S59 S69
11. Tashkin D. P., Elashoff R., Clements P. J., Goldin J., Roth M. D., Furst D. E., Arriola E., Silver R., Strange C., Bolster M., Seibold J. R., Riley D. J., Hsu V. M., Varga J., Schraufnagel D. E., Theodore A., Simms R., Wise R., Wigley F., White B., Steen V., Read C., Mayes M., Parsley E., Mubarak K., Connolly M. K., Golden J., Olman M., Fessler B., Rothfield N., Metersky M., Cyclophosphamide versus placebo in scleroderma lung disease New England Journal of Medicine 2006 354 25 2655 2666
12. Tashkin D. P., Elashoff R., Clements P. J., Goldin J., Roth M. D., Furst D. E., Arriola E., Silver R., Strange C., Bolster M., Seibold J. R., Riley D. J., Hsu V. M., Varga J., Schraufnagel D. E., Theodore A., Simms R., Wise R., Wigley F., White B., Steen V., Read C., Mayes M., Parsley E., Mubarak K., Connolly M. K., Golden J., Olman M., Fessler B., Rothfield N., Metersky M., Cyclophosphamide versus placebo in scleroderma lung disease New England Journal of Medicine 2006 354 25 2655 2666
13. Tashkin D. P., Elashoff R., Clements P. J., Roth M. D., Furst D. E., Silver R. M., Goldin J., Arriola E., Strange C., Bolster M. B., Seibold J. R., Riley D. J., Hsu V. M., Varga J., Schraufnagel D., Theodore A., Simms R., Wise R., Wigley F., White B., Steen V., Read C., Mayes M., Parsley E., Mubarak K., Connolly M. K., Golden J., Olman M., Fessler B., Rothfield N., Metersky M., Khanna D., Li N., Li G., Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease American Journal of Respiratory and Critical Care Medicine 2007 176 10 1026 1034 (Pubitemid 350127847)
14. Goldin J., Elashoff R., Kim H. J., Yan X., Lynch D., Strollo D., Roth M. D., Clements P., Furst D. E., Khanna D., Vasunilashorn S., Li G., Tashkin D. P., Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study Chest 2009 136 5 1333 1340
15. Goldin J. G., Lynch D. A., Strollo D. C., Suh R. D., Schraufnagel D. E., Clements P. J., Elashoff R. M., Furst D. E., Vasunilashorn S., McNitt-Gray M. F., Brown M. S., Roth M. D., Tashkin D. P., High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease Chest 2008 134 2 358 367
16. Roth M. D., Tseng C.-H., Clements P. J., Furst D. E., Tashkin D. P., Goldin J. G., Khanna D., Kleerup E. C., Li N., Elashoff D., Elashoff R. M., Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease Arthritis and Rheumatism 2011 63 9 2797 2808
17. Allison A. C., Eugui E. M., Mycophenolate mofetil and its mechanisms of action Immunopharmacology 2000 47 2-3 85 118 (Pubitemid 30394534)
18. Allison A. C., Eugui E. M., Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection Transplantation 2005 80 2 S181 S190
19. Allison A. C., Mechanisms of action of mycophenolate mofetil Lupus 2005 14 1 s2 s8
20. Ciancio G., Burke G. W., Gaynor J. J., Mattiazzi A., Roth D., Kupin W., Nicolas M., Ruiz P., Rosen A., Miller J., A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (neoral) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year Transplantation 2004 77 2 244 251 (Pubitemid 38155754)
21. Ciancio G., Miller J., Gonwa T. A., Review of major clinical trial with mycophenolate mofetil in renal transplantation Transplantation 2005 80 2 S191 S200
22. Altschuler E. L., Consideration of mycophenolate mofetil for idiopathic pulmonary fibrosis Medical Hypotheses 2001 57 6 701 702 (Pubitemid 34014367)
23. Waller J. R., Brook N. R., Bicknell G. R., Murphy G. J., Nicholson M. L., Mycophenolate mofetil inhibits intimal hyperplasia and attenuates the expression of genes favouring smooth muscle cell proliferation and migration Transplantation Proceedings 2005 37 1 164 166 (Pubitemid 40459724)
24. Simeon-Aznar C. P., Fonollosa-Pla V., Tolosa-Vilella C., Selva-O'Callaghan A., Solans-Laqué R., Vilardell-Tarres M., Effect of mycophenolate sodium in scleroderma-related interstitial lung disease Clinical Rheumatology 2011 30 11 1393 1398
25. Gerbino A. J., Goss C. H., Molitor J. A., Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease Chest 2008 133 2 455 460 (Pubitemid 351272405)
26. Koutroumpas A., Ziogas A., Alexiou I., Barouta G., Sakkas L. I., Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease Clinical Rheumatology 2010 1 2
27. Liossis S. N. C., Bounas A., Andonopoulos A. P., Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease Rheumatology 2006 45 8 1005 1008 (Pubitemid 44283057)
28. Zamora A. C., Wolters P. J., Collard H. R., Connolly M. K., Elicker B. M., Webb W. R., King T. E., Golden J. A., Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease Respiratory Medicine 2008 102 1 150 155 (Pubitemid 350151821)
29. Steen V. D., Graham G., Conte C., Owens G., Medsger T. A., Isolated diffusing capacity reduction in systemic sclerosis Arthritis and Rheumatism 1992 35 7 765 770
30. Nihtyanova S. I., Brough G. M., Black C. M., Denton C. P., Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-A retrospective analysis Rheumatology 2007 46 3 442 445 (Pubitemid 46344656)
31. Plastiras S. C., Vlachoyiannopoulos P. G., Tzelepis G. E., Mycophenolate mofetil for interstitial lung disease in scleroderma [1] Rheumatology 2006 45 12 1572 (Pubitemid 44817068)
32. Swigris J. J., Olson A. L., Fischer A., Lynch D. A., Cosgrove G. P., Frankel S. K., Meehan R. T., Brown K. K., Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease Chest 2006 130 1 30 36 (Pubitemid 44116838)
33. Steen V., Predictors of end stage lung disease in systemic sclerosis Annals of the Rheumatic Diseases 2003 62 2 97 99 (Pubitemid 36135382)